Back to search

Article

Real-world survival of EGFR-mutated NSCLC with leptomeningeal metastases: prognostic impact of TKIs and local multidisciplinary treatment from the CLM-tree registry

2026-05-20

Abstract excerpt

<title>Abstract</title> <p> Background Leptomeningeal metastases (LM) in EGFR-mutated non–small-cell lung cancer (NSCLC) confer poor prognosis. The value of local multidisciplinary treatment (L-MDT) in the era of third-generation EGFR tyrosine kinase inhibitors (TKIs) remains uncertain. Methods We retrospectively analyzed patients with EGFR-mutated NSCLC and LM from the multicenter CLM-tree registry (NCT067189...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7a85f75f-e555-5297-acf7-0710f029d9c2
DOI
10.21203/rs.3.rs-9228634/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world survival of EGFR-mutated NSCLC with leptomeningeal metastases: prognostic impact of TKIs and local multidisciplinary treatment from the CLM-tree registryDOI 10.21203/rs.3.rs-9228634/v1
Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study.Semantic proximity
Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.Semantic proximity
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.Semantic proximity
Treatment and survival of analysis in patients with leptomeningeal metastasis from lung cancerSemantic proximity
Clinical Outcomes of Patients with Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era.Semantic proximity
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.Semantic proximity
[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Semantic proximity
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).Semantic proximity
Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity
Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.Semantic proximity
Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.Semantic proximity
Combined Furmonertinib and Intrathecal Chemotherapy for Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: Efficacy, Safety, and CSF Drug ConcentrationsSemantic proximity
Select a neighboring publication to make it the new centre.